Brief: Xilio Therapeutics Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
19/01/2024 21:53
Jan 19 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS INC: ON JANUARY 19, 2024 CO RECEIVED
NOTICE
OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Further company coverage: XLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla